Table 1 Baseline patient characteristics by metformin status, in patients with at least one prescription in 6 months prior to admission with first acute AMI
|  | Metformin (N = 2576, 63.9%) | Other drug (N = 1454, 36.1%) |
|---|---|---|
Age (years), mean (SD)** | 71.29 (11.2) | 76.10 (10.9) |
Female, n (%)* | 1001 (38.9) | 624 (42.9) |
IMD, n (%) | ||
 < 8.5 (Least deprived) | 431 (16.8) | 252 (17.4) |
 8.5– < 34.18 | 1657 (64.6) | 938 (64.8) |
 ≥ 34.18 (Most deprived) | 478 (18.6) | 258 (17.8) |
BMI (kg/m2), mean (SD)** | ||
 < 18.5 | 23 (0.9) | 27 (2.0) |
 18.5– < 25 | 490 (19.8) | 388 (29.0) |
 25– < 30 | 912 (36.8) | 535 (40.0) |
 30– < 35 | 703 (28.4) | 275 (20.5) |
 ≥35 | 352 (14.2) | 115 (8.6) |
Smoking status, n (%)* | ||
 Never-smoker | 1104 (44.6) | 688 (50.4) |
 Ex-smoker | 1011 (40.8) | 493 (36.1) |
 Current smoker | 363 (14.7) | 183 (13.4) |
Hypertensive, n (%)* | 2186 (84.9) | 1178 (81.0) |
Systolic blood pressure (mmHg), mean (SD)* | 140.50 (23.6) | 138.38 (21.8) |
HbA1c (mmol/mol), mean (SD)** | 61.48 (17.39) | 58.99 (17.16) |
Diabetes medication, n (%) | ||
 Sulphonylureas, n (%)** | 1310 (50.9) | 1400 (96.3) |
 Thiazolidinediones, n (%) | 217 (8.4) | 146 (10.0) |
 Acarbose, n (%) | 69 (2.7) | 37 (2.5) |
 DPP4 inhibitors, n (%)* | 8 (0.3) | 13 (0.9) |
 GLP1 agonists, n (%) | 3 (0.1) | 2 (0.1) |
 Meglitinides, n (%) | 21 (0.8) | 15 (1.0) |
 Insulin, n (%)** | 440 (17.1) | 113 (7.8) |
 HDL serum cholesterol (mmol/L), mean (SD) | 1.18 (0.4) | 1.20 (0.4) |
 Total serum cholesterol (mmol/L), mean (SD)** | 4.43 (1.2) | 4.58 (1.3) |
History of cardiovascular disease | ||
 HF, n (%)* | 652 (25.3) | 432 (29.7) |
 CHD, n (%) | 1064 (41.3) | 593 (40.9) |
 Ischaemic stroke, n (%) | 89 (3.5) | 49 (3.4) |
 Stroke, n (%) | 338 (13.1) | 198 (13.6) |
 TIA, n (%) | 218 (8.5) | 135 (9.3) |
 PAD, n (%)* | 472 (18.3) | 307 (21.1) |
 AAA, n (%)* | 441 (17.1) | 292 (20.1) |